Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
June 25 2024 - 9:00AM
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting
Progress in Accessibility and R&D Innovation
Samsung Bioepis Co., Ltd. today issued its 2024 sustainability
report, underscoring its progress toward building more sustainable
and socially responsible practices in access to medicines, R&D
innovation, and product quality and patient safety.
“In pursuit of our vision ‘Passion for Health’,
we ensure that our environmental, social and governance
responsibilities are systematically managed. This year’s
sustainability report reflects our ongoing efforts to deliver
positive social impact to patients while maintaining transparency
and accountability in all aspects of our operations,” said
Christopher Hansung Ko, President and Chief Executive Officer at
Samsung Bioepis. “Through our operations, we make sure that we’re
making positive contribution to the communities we serve and also
fostering long-term value for all of our stakeholders including
patients, communities and governments.”
The annual report provides a comprehensive
overview of Samsung Bioepis’ performance and management of the
company’s commitment to sustainability, and key highlights of the
report are as follows:
1) Access to
Medicines: In 2023 alone, Samsung Bioepis’ seven biosimilar
medicines have been used to treat approximately 430,000 patients
across 40 countries. 2023 witnessed biosimilar launches
across several therapeutic areas, including adalimumab biosimilar
launch in the United States and ophthalmology and hematology
biosimilar launches in Europe. Based on assessment across 10
countries, our biosimilars have been estimated to create 2.5
trillion KRW (1.9 billion USD) social impact by helping healthcare
systems achieve cost savings and by improving patients and
caregivers quality of life and work productivity.i
2) R&D
Innovation: We are continuing to optimize our biosimilar
development platform through Quality by Design (QbD), Tollgate
Systems, and Failure Modes and Effects Analysis (FMEA). We are able
to develop biosimilars more effectively at a faster speed through
higher productivity of cell line development, optimization of
scale-up system, automation of analysis methods, digitalization of
data management, and computerized modeling for process development.
In addition, we are expanding R&D into antibody drug
conjugates (ADC) and cell and gene therapy (CGT) by collaborating
with biotech companies for research and development of drugs to
explore new business growth opportunities.
3) Product
Quality and Patient Safety: We have implemented a very
stringent quality management system which allows us to detect
potential quality risks in advance and manage them effectively in a
timely manner. This has allowed us to provide biosimilar medicines
that are quality-assured from cell line development to commercial
manufacturing. As a result, we have not received any
warning letter from regulatory agencies, for 35 inspections which
were conducted throughout 2021-2023.
In addition, Samsung Bioepis received two ISO
certifications: ISO 27001 (Information Security Management System)
and ISO 45001 (Occupational Safety & Health Management System)
in August 2023, underscoring the company’s commitment to providing
healthy and safe workplace environment and ensuring information
security. Since 2022, together with Samsung Biologics, Samsung
Bioepis is committed to achieving Net Zero by 2050, as part of the
global effort to tackle climate change. At the heart of the
commitment is achieving net zero carbon emissions (Scope 1 &
Scope 2) by converting our direct and indirect energy sources to
renewable energy in mid-to-long term.
The company’s report is formulated in the Global
Reporting Initiative (GRI) Standards and details activities and
achievements that are aligned with the Sustainability Accounting
Standards Board (SASB) Standards. Samsung Bioepis’ detailed ESG
performance can be found in the full report:
https://bit.ly/3L0i7CM
Assessing our ESG Impact
Samsung Bioepis has been conducting a double
materiality assessment to assess and prioritize 10 material issues:
1) product responsibility and safety, 2) access to medicines, 3)
supply chain ESG risk management, 4) R&D and product
innovation, 5) ethics and compliance management, 6) climate change,
7) governance, 8) human resources and talent management, 9) product
lifecycle quality management, and 10) ethics for clinical trial and
animal testing. These issues are assessed based on both financial
and impact materiality, and are being managed based on key metrics
and targets set for each issue. We also engage with our
stakeholders – customers, employees, suppliers, vendors, investors,
shareholders, academic institutions, local communities,
governments, media, and trade associations – and incorporate their
feedback when assessing the material issues and our ESG
performance.
About Samsung Bioepis Co.,
Ltd.
Established in 2012, Samsung Bioepis is a
biopharmaceutical company committed to realizing healthcare that is
accessible to everyone. Through innovations in product development
and a firm commitment to quality, Samsung Bioepis aims to become
the world's leading biopharmaceutical company. Samsung Bioepis
continues to advance a broad pipeline of biosimilar candidates that
cover a spectrum of therapeutic areas, including immunology,
oncology, ophthalmology, hematology and endocrinology. For more
information, please visit: www.samsungbioepis.com and follow us on
social media – X, LinkedIn.
MEDIA CONTACTYoon Kim,
yoon1.kim@samsung.comAnna Nayun Kim, nayun86.kim@samsung.com
_____________________________
i 10 countries are the United States (US), Germany,
France, Italy, Spain, United Kingdom (UK), Republic of Korea,
Canada, Australia, and Brazil.